A chemical engineer and synthetic biologist by training, Mr. Kendall was an early employee with LS9, Inc. (acquired by Genomatica), where he developed an automated experimentation and analysis platform for their synthetic biology platform. He next scaled commercial processes for Cobalt Technologies. Mr. Kendall is a recipient of the President’s Green Chemistry Challenge Award. He holds a B.S. and M.S. in Chemical Engineering from Stanford University, where he worked with Jim Swartz on cell-free protein synthesis, and an M.B.A. from the University of Chicago.
Sean Kendall is a partner at ARCH and based in London. He focuses on identifying and evaluating new life science technologies and provides operating assistance to early-stage portfolio companies. He contributed to the formation and funding of Vizgen, AIRNA, Scale Biosciences, and Lightcast Discovery, and led business development efforts for Encodia, Singleron Biotechnologies, Twist Bioscience (TWST), and Ultivue. He is an active board member at Encodia and sits as a board observer at Vizgen and others, having previously served as an observer at Twist. Mr. Kendall also supports ARCH Technical Services, where he has encouraged breakthrough innovations in electronics, sustainable materials, energy, and more via corporate partnering and investment.
ARCH Ventures has backed disruptive science companies with as little as $50K to as much as hundreds of millions of dollars per company for the past 30 years. They are one of the most successful early-stage investors in the U.S., having financed and developed more than 150 companies, including 47 which have reached valuations exceeding $1 billion.